Kyverna Therapeutics, Inc.
KYTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $143 | $20,209 | $774 | $774 |
| - Cash | $97 | $35 | $38 | $76 |
| + Debt | $8 | $9 | $11 | $6 |
| Enterprise Value | $55 | $20,183 | $747 | $704 |
| Revenue | $0 | $0 | $7 | $6 |
| % Growth | – | -100% | 24.2% | – |
| Gross Profit | -$2 | -$2 | $7 | $6 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$125 | -$58 | -$28 | -$26 |
| % Margin | – | – | -395.4% | -455.5% |
| Net Income | -$127 | -$60 | -$29 | -$26 |
| % Margin | – | – | -411.3% | -465.9% |
| EPS Diluted | -3.33 | -0 | -1.12 | -1.02 |
| % Growth | -3,329,900% | 100% | -9.8% | – |
| Operating Cash Flow | -$114 | -$52 | -$36 | -$22 |
| Capital Expenditures | -$2 | -$1 | -$1 | -$1 |
| Free Cash Flow | -$116 | -$53 | -$37 | -$23 |